Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.32 - $8.27 $23,692 - $612,310
74,040 New
74,040 $28,000
Q2 2022

Aug 15, 2022

SELL
$0.58 - $1.13 $106,105 - $206,723
-182,941 Reduced 71.1%
74,365 $44,000
Q1 2022

May 11, 2022

SELL
$0.73 - $1.81 $1,262 - $3,131
-1,730 Reduced 0.67%
257,306 $260,000
Q4 2021

Feb 11, 2022

BUY
$1.66 - $2.64 $10,205 - $16,230
6,148 Added 2.43%
259,036 $430,000
Q3 2021

Nov 12, 2021

BUY
$2.58 - $3.36 $49,056 - $63,887
19,014 Added 8.13%
252,888 $680,000
Q2 2021

Aug 11, 2021

BUY
$2.7 - $3.81 $140,167 - $197,792
51,914 Added 28.53%
233,874 $776,000
Q1 2021

May 13, 2021

BUY
$3.02 - $5.16 $504 - $861
167 Added 0.09%
181,960 $604,000
Q4 2020

Feb 09, 2021

BUY
$2.66 - $4.18 $171,676 - $269,777
64,540 Added 55.04%
181,793 $688,000
Q3 2020

Nov 12, 2020

SELL
$3.01 - $3.88 $8,307 - $10,708
-2,760 Reduced 2.3%
117,253 $369,000
Q2 2020

Aug 12, 2020

SELL
$2.33 - $4.6 $18,595 - $36,712
-7,981 Reduced 6.24%
120,013 $381,000
Q1 2020

May 06, 2020

SELL
$1.91 - $4.52 $1,453 - $3,439
-761 Reduced 0.59%
127,994 $343,000
Q4 2019

Feb 14, 2020

BUY
$2.57 - $4.08 $11,629 - $18,462
4,525 Added 3.64%
128,755 $525,000
Q3 2019

Nov 07, 2019

BUY
$2.74 - $4.65 $77,043 - $130,748
28,118 Added 29.26%
124,230 $404,000
Q2 2019

Aug 12, 2019

BUY
$2.66 - $6.28 $109,538 - $258,610
41,180 Added 74.97%
96,112 $354,000
Q1 2019

May 14, 2019

SELL
$2.95 - $5.61 $2,171 - $4,128
-736 Reduced 1.32%
54,932 $188,000
Q4 2018

Feb 11, 2019

BUY
$2.3 - $5.78 $27,855 - $70,001
12,111 Added 27.8%
55,668 $163,000
Q2 2018

Aug 06, 2018

BUY
$6.68 - $11.0 $208,395 - $343,167
31,197 Added 252.4%
43,557 $300,000
Q1 2018

May 15, 2018

BUY
$10.14 - $12.38 $125,330 - $153,016
12,360 New
12,360 $136,000

Others Institutions Holding MBIO

About MUSTANG BIO, INC.


  • Ticker MBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,222,000
  • Market Cap $22.1M
  • Description
  • Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...
More about MBIO
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.